Dataset related to the article "Cryoballoon atrial fibrillation ablation: Single-center safety and efficacy data using a novel cryoballoon technology compared to a historical balloon platform"
| Main Authors: | Kochi, Adriano, Moltrasio, Massimo, Tundo, Fabrizio, Riva, Stefania, Ascione, Ciro, Dessanaia, Maria Antonietta, Pizzamiglio, Francesca, Vettor, Giulia, Cellucci, Selene, Gasperetti, Alessio, Tondo, Claudio, Fassini, Gaetano |
|---|---|
| Format: | info dataset Journal |
| Terbitan: |
, 2022
|
| Online Access: |
https://zenodo.org/record/6353334 |
Daftar Isi:
- This record contains raw data related to the article "Cryoballoon atrial fibrillation ablation: Single-center safety and efficacy data using a novel cryoballoon technology compared to a historical balloon platform". Abstract Introduction: Catheter ablation is superior to drugs regarding atrial fibrillation (AF) recurrence, symptoms improvement, and mortality reduction in heart failure. POLARxTM is a novel cryoballoon, with technical improvements seeking to improve outcomes. So far, its clinical evidence is restricted to a case report. Methods: To compare the POLARxTM cryoballoon procedural safety and efficacy to the already established Arctic Front Advance PROTM (AFAP) in a single-center cohort study, consecutive patients undergoing AF cryoablation with the POLARxTM were enrolled. Data were prospectively gathered. POLARxTM patients were compared with a historical cohort of patients submitted to AF cryoablation with the AFAP. Results: Seventy patients were analyzed, 20 in POLARxTM, and 50 in the AFAP group. They all underwent first-time pulmonary vein isolation, 77% were male, 94% had paroxysmal AF, median age was 62.5 years, median CHA2 DS2 -VASc 1, left-atrium size 34 ml/m2, and 65% were receiving anticoagulation. The primary end-point, all pulmonary veins isolation, was 100% in both groups. The complication rate was similar (0% POLARxTM vs. 5.7% AFAP, p = .39). The median total procedural time was longer in the POLARxTM group (90 min vs. 60 min, p < .001), but the overall time-to-isolation (TTI; 44.8 s vs. 39 s, p = .253) and ablation time (15 min vs. 13.7 min, p = .122) was similar between POLARxTM and AFAP groups, respectively. Despite equal TTI, the POLARxTM had a lower minimal temperature reached (-57°C vs -47°C, p < .001). Conclusion: The novel POLARxTM cryoballoon had similar efficacy and safety compared with the AFAP. It was also associated with longer procedural times, similar TTI, and lower minimum temperature reached.